Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT

Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. Af...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jinhua, Lin, QiaoXian, Chen, Qi, Xu, Jingjing, Chen, Dabin, Chen, Renli, Lin, Kangni, Zhu, Haojie, Ye, Chenjing, Luo, Xiaofeng, Chen, Shaozhen, Kong, Hui, Lin, Qiong, Li, Nan, Lin, Xu, Chen, Zhizhe, Hu, Jianda, Yang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014299/
https://www.ncbi.nlm.nih.gov/pubmed/36936790
http://dx.doi.org/10.1016/j.isci.2023.106290
_version_ 1784906964854112256
author Ren, Jinhua
Lin, QiaoXian
Chen, Qi
Xu, Jingjing
Chen, Dabin
Chen, Renli
Lin, Kangni
Zhu, Haojie
Ye, Chenjing
Luo, Xiaofeng
Chen, Shaozhen
Kong, Hui
Lin, Qiong
Li, Nan
Lin, Xu
Chen, Zhizhe
Hu, Jianda
Yang, Ting
author_facet Ren, Jinhua
Lin, QiaoXian
Chen, Qi
Xu, Jingjing
Chen, Dabin
Chen, Renli
Lin, Kangni
Zhu, Haojie
Ye, Chenjing
Luo, Xiaofeng
Chen, Shaozhen
Kong, Hui
Lin, Qiong
Li, Nan
Lin, Xu
Chen, Zhizhe
Hu, Jianda
Yang, Ting
author_sort Ren, Jinhua
collection PubMed
description Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival.
format Online
Article
Text
id pubmed-10014299
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100142992023-03-16 Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT Ren, Jinhua Lin, QiaoXian Chen, Qi Xu, Jingjing Chen, Dabin Chen, Renli Lin, Kangni Zhu, Haojie Ye, Chenjing Luo, Xiaofeng Chen, Shaozhen Kong, Hui Lin, Qiong Li, Nan Lin, Xu Chen, Zhizhe Hu, Jianda Yang, Ting iScience Article Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival. Elsevier 2023-02-28 /pmc/articles/PMC10014299/ /pubmed/36936790 http://dx.doi.org/10.1016/j.isci.2023.106290 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ren, Jinhua
Lin, QiaoXian
Chen, Qi
Xu, Jingjing
Chen, Dabin
Chen, Renli
Lin, Kangni
Zhu, Haojie
Ye, Chenjing
Luo, Xiaofeng
Chen, Shaozhen
Kong, Hui
Lin, Qiong
Li, Nan
Lin, Xu
Chen, Zhizhe
Hu, Jianda
Yang, Ting
Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title_full Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title_fullStr Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title_full_unstemmed Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title_short Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
title_sort adoptive immune transfer from donors offers anti-hbv protection to hbsab-negative patients after allo-hsct
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014299/
https://www.ncbi.nlm.nih.gov/pubmed/36936790
http://dx.doi.org/10.1016/j.isci.2023.106290
work_keys_str_mv AT renjinhua adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT linqiaoxian adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT chenqi adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT xujingjing adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT chendabin adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT chenrenli adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT linkangni adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT zhuhaojie adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT yechenjing adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT luoxiaofeng adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT chenshaozhen adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT konghui adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT linqiong adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT linan adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT linxu adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT chenzhizhe adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT hujianda adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct
AT yangting adoptiveimmunetransferfromdonorsoffersantihbvprotectiontohbsabnegativepatientsafterallohsct

Ejemplares similares